Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates
Bayer, Brigham and Mass General open lung disease-focused lab
Bayer AG (Xetra:BAYN) will invest more than $30 million over five years to fund research into new treatments for chronic lung diseases, such as chronic obstructive pulmonary disease, at a joint lab launched by the pharma, Massachusetts General Hospital and Brigham and Women's Hospital. The lab will be at Brigham and Women's, and the three organizations will share rights to any findings.
Auransa, Atomwise publish preclinical data on AI-derived compounds
Auransa Inc. showed lead candidate AU-409, whose undisclosed target was identified using the company's Subtypes Markers Targets Redefining (SMarTR) AI platform, decreased tumor burden in a mouse model of hepatocellular carcinoma; data were presented at the International Liver Cancer Association meeting in Chicago. ...